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To the Editor:
Therapy-related leukaemia is a life-threatening complication
of cancer treatment. The prognosis is poor and incidence is
increasing, mainly due to the increasing survival from primary
cancers, leading to an emerging major healthcare problem [1].
Currently two groups of tMN are recognised: the first,
accounting for ~80% of cases, is characterised by exposure to
alkylating agents, a latency period of 5–6 years, a complex or
monosomal karyotype and/or mutations in TP53 [2]. These
mutations have been detected in samples pre-dating therapy
exposure [3] and presence of clonal haematopoiesis (CH)
prior to cancer treatment is associated with a markedly
increased risk of tMN with estimated hazard ratios of
5.8–13.7 [4, 5], indicating that cancer therapy may drive the
expansion of pre-existing mutated clones, eventually leading
to malignant transformation.
The second group of tMN accounting for ~20% of cases
is characterised by exposure to topoisomerase II (topo2)
targeting agents, a latency period of 1–2 years and presence
of recurrent fusion genes identical to those seen in de novo
AML [6, 7]. In these cases, there is evidence that drugs
targeting topo2 directly initiate chromosome rearrangements:
in the presence of mitoxantrone or etoposide, topo2 cleaves
the PML and RARA loci at the precise base pair positions
observed to be fusion breakpoint junctions in patients who
develop therapy-related acute promyelocytic leukaemia
(tAPL) after exposure to these agents [8, 9].
Fusion-gene associated chromosome translocations are
widely regarded as primary leukaemia-initiating events in
AML. Genome-wide studies show striking exclusivity between
fusion genes and other mutations shown to be leukaemia-
initiating events. For example, mutations in DNMT3A are
frequent in AML and are associated with a preleukaemic state
[10–12]. These mutations either do not occur or are rare in
leukaemias with fusion genes [11–13]. Thus, two distinct
processes that lead to the generation of tMN appear to mirror
two separate mechanisms of de novo leukaemogenesis, with
two distinct types of primary leukaemia-initiating event (fusion
genes and preleukaemic mutations, respectively).
The relationship between CH and therapy-related leu-
kaemias with recurrent chromosome translocations has not
previously been investigated. Here, we focussed on a
molecularly defined group of patients with PML-RARA+
tAPL and present evidence that in these patients, in contrast
to de novo APL, chromosome translocations may be sec-
ondary events, arising on a background of pre-existing CH.
We first performed whole-exome sequencing of 55 cases
of de novo (dnAPL) and 13 cases of therapy-related APL
(tAPL, exposure details shown in Supplementary Table 1).
Information regarding library preparation, sequencing and
analysis is provided in the Supplementary data. We identified
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a mean of 17.1 and 15.3 somatic mutations per exome,
respectively (p= 0.59). There were no significant differences
in the numbers of non-synonymous single nucleotide variants
(SNV, mean 8.8 vs. 8.2, p= 0.69) synonymous SNV (7.0 vs.
5.8, p= 0.49) or InDel mutations (1.3 vs. 1.4, p= 0.72).
To identify recurrent APL-associated mutations, we com-
bined this data set with three other whole-exome sequencing
studies of APL [12–14] for a total of 164 sequenced cases, and
identified 70 recurrently mutated genes (i.e. mutated in two or
more cases of APL). We identified a mean of 2.0 and 2.2
recurrent mutations per patient for dnAPL and tAPL, respec-
tively (median 2 range 0–6 and median 2 range 0–5, p= 0.74,
Supplementary Fig. 1). There was no clear difference in the
pattern of mutated genes. There were three genes that were
mutated in tAPL but not dnAPL (AP3D1, DNMT3A and
GPR158, Fisher’s exact test, p= 0.035).
We next analysed samples taken in molecular complete
remission (mCR, defined as the absence of PML-RARA or
RARA-PML fusion transcripts at a sensitivity of at least 1:104)
from all 13 tAPL patients and a subset of 22 dnAPL patients
who were matched in age and other clinical characteristics
(Supplementary Table 2). Targeted, error-corrected next-
generation sequencing (EC-NGS) was performed using
the HaloPlexHS system (Agilent Technologies, Santa Clara,
California) using probes designed to capture all somatic
mutations detected at diagnosis (i.e. APL-associated
mutations). The mean depth of sequencing was 27,111× with
97 and 84% of bases covered at >1000× and >10,000×,
respectively. In the tAPL group, we identified persistence of a
median of 2.5 APL-associated mutations in mCR (range 1–8)
in four patients, with a median variant allele frequency of 6%
(range 0.4–13.9%, Fig. 1a). Hereafter we refer to these as
persistent APL-associated mutations. One potential driver
mutation was present in each case, these were DNMT3A (two
patients) PPM1D and MYCN (Fig. 2a, b). We did not find the
persistence of APL-associated mutations in any patient with
dnAPL (Fisher’s exact test, p= 0.01). We did not observe an
association between persistence of APL-associated mutations
and patient age, type of primary cancer, type of treatment
received or latency period, however this small cohort pro-
vided limited power to detect such associations.
We then performed EC-NGS using a separate Halo-
PlexHS library designed to capture the entire coding region
of all genes identified as bearing persistent mutations in
mCR, together with those of other genes previously asso-
ciated with CH (a total of 87 genes, listed in Supplementary
Table 3). Mean sequencing depth was 3378× with 98 and
85% of bases covered at >100× and >1000×, respectively.
This method identified APL-unrelated mutations (i.e.
mutations not present in the major clone at diagnosis) in
both the tAPL and dnAPL groups (3/21 dnAPL and 2/13
tAPL, p= 1.0, Fig. 1). These mutations either emerged or
Fig. 1 Presence of somatic mutations during molecular complete
remission. Mutations identified by error-corrected next-generation
sequencing performed on bone marrow samples taken during mole-
cular complete remission after treatment for de novo (n= 22) and
therapy-related APL are shown. All remission samples tested negative
for PML-RARA fusion transcripts at a sensitivity of at least 1:104.
Variant allele frequencies (%) at diagnosis and remission are shown.
Mutations present at a frequency of <1% at APL diagnosis (i.e. APL-
unrelated mutations) are highlighted in blue. Mutations which were
present with a frequency of >30% at APL diagnosis (i.e. APL-
associated mutations) are highlighted in red.
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increased in frequency after treatment and were mainly in
genes previously linked with CH, consistent with pre-
viously described therapy emergent or rising clones [15].
In order to determine whether persistent APL-associated
mutations were present prior to cancer therapy, tumour
biopsies were obtained from time of primary cancer diag-
nosis for three patients (UPN T2, T10 and T11) and ana-
lysed by EC-NGS. Using a VAF cut-off at 0.1% we
identified APL-associated mutations in four samples from
two patients at a median VAF of 0.8% (range 0.6–2.1%,
Fig. 2c). The mutations were PPM1D (exon 6, 1 bp dele-
tion) in malignant lymph node samples obtained 48
and 15 months prior to APL diagnosis from patient T2, and
DNMT3A (exon 10, 1 bp insertion) in breast and lymph
node samples both obtained 32 months prior to APL diag-
nosis from patient T11. For patient T10 the relevant muta-
tion was not identified.
To identify the cell lineage(s) harbouring persistent APL-
associated mutations, we obtained cryopreserved mono-
nuclear cell preparations from bone marrow samples taken
during mCR from the same three patients. Flow sorted T
and B lymphocytes, monocytes, granulocytes and CD34+
progenitors were analysed using amplicon-NGS (further
details are provided in the Supplementary data). In each
case, the predicted driver mutation was present in the hae-
matopoietic stem and progenitor cell containing CD34+
fraction at a median VAF of 3.2% (range 0.5–5.2%) and
was present in both the myeloid and lymphoid lineages,
consistent with origin in a multipotent haematopoietic stem
or progenitor cell (Fig. 2d).
Finally, to establish whether persistent APL-associated
mutations were present in functional haematopoietic stem
cells, we injected cryopreserved mononuclear cells taken at
diagnosis of tAPL from patients T2 and T8 into irradiated
Fig. 2 APL-associated mutations persist in molecular complete
remission, can occur prior to chemotherapy exposure and affect
multiple haematopoietic lineages. A Variant allele frequencies
(VAF) of somatic mutations detected at diagnosis of therapy-related
APL are plotted for both the APL diagnosis (APL) and molecular
complete remission (mCR) time points for four patients in whom these
remained detectable. Predicted driver (PD) mutations are highlighted
in blue. B Browser views showing the presence of PD mutations in
mCR samples. C Change in VAF of APL-associated mutations (red
line) and PML-RARA fusion transcript levels (blue line) over time,
with date of tAPL diagnosis plotted as time 0. D VAF of APL-
associated PD mutations in sorted cell populations obtained from
samples taken in molecular complete remission (the relevant sample is
marked with an asterisk in C). CD34+= CD34+ stem and progenitor
cells, B= CD19+ B lymphocytes, T= CD3+ T-lymphocytes, M=
CD33+ myeloid cells.
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NSG mice. A total of 1 × 106 cells were injected into
three mice for each patient. We detected human engraftment
in 1/3 recipient mice at 18 and 22 weeks from
injection for patient T2 and T8, respectively. After sacrifice,
flow cytometry analysis demonstrated human myeloid and
B-lymphoid engraftment in both mice (Supplementary
Fig. 2). Sorted human CD45+ cells tested negative for
PML-RARA and RARA-PML fusion transcripts by RT-
qPCR and were also negative for the fusion by fluorescence
in-situ hybridisation. DNA extracted from this population
was analysed by amplicon-NGS and identified the
tAPL-associated predicted driver mutation in each case
(T2 PPM1D exon 6, 1 bp del, VAF 2.9%; T8 MYCN exon
3, 6 bp ins, VAF 1.4%). Interestingly, the observed allele
frequencies indicated that the clone harbouring the somatic
mutation contributed a minor component to the human
engraftment in each case, suggesting that the mutation
did not provide a significant selective advantage in this
situation.
Taken together these results indicate that in therapy-
related but not de novo APL, the PML-RARA fusion may be
a secondary event, occurring on a background of pre-
leukaemic CH. It is intriguing that this phenomenon was
only observed in tAPL. We cannot exclude that this
mechanism may rarely underlie de novo APL and speculate
that this observation may be accounted for by differences in
prevalence, clone size and mutational spectrum of CH
between patients exposed to chemotherapy and individuals
with no history of cancer.
These findings contribute to the current understanding
of the relationship between CH and leukaemia and chal-
lenge the previous assumption that fusion genes are always
primary transforming events. It will be of interest to
establish the role of CH in other types of tMN with
balanced translocations, particularly for patients with
KMT2A rearrangements, where co-operating mutations are
not always necessary. Finally, the high prevalence of CH
after treatment for tAPL (observed in 4/13 or 31% of
patients studied, with the presence of multiple independent
clones in 2/13) also has important implications for treat-
ment of tAPL, a condition where chemotherapy-free
treatment in the form of arsenic trioxide and ATRA is
already available.
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